PIK3CA and breast cancer: Similar to breast cancer, EC has a large proportion with high sensitivity to estrogen signaling, ~92% of type I and ~72% of type II ECs were ER-positive [57], particularly within the POLE, MSI, and CNL molecular subtypes [9], making them potential candidates for combined PI3K and endocrine therapy.